1. WHO. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016-2021: Actions for Impact. 2021 [Available from: https://www.who.int/publications/i/item/9789240027077.
2.
PIB) N.I.Z.P.P.P.I.B.N.P. Choroby Zakaźne I Zatrucia W Polsce W 2022 Roku 2022 [Available from: https://wwwold.pzh.gov.pl/oldpage/epimeld/2022/Ch_2022_Wstepne_dane.pdf
3.
Tudor M.E., Al Aboud A.M., Leslie S.W., Gossman W.: Syphilis of chapter. [In:] StatPearls. (red.), Place, 2023,
4.
Peeling R.W., Hook E.W. 3rd: The pathogenesis of syphilis: the Great Mimicker, revisited. J Pathol 2006, 208, 224-232.
5.
Janier M., Unemo M., Dupin N., Tiplica G.S., Potocnik M., Patel R.: 2020 European guideline on the management of syphilis. J Eur Acad Dermatol Venereol 2021, 35, 574-588.
6.
Gjestland T.: The Oslo study of untreated syphilis; an epidemiologic investigation of the natural course of the syphilitic infection based upon a re-study of the Boeck-Bruusgaard material. Acta Derm Venereol Suppl (Stockh) 1955, 35, 3-368.
7.
Nayak S., Acharjya B.: VDRL test and its interpretation. Indian J Dermatol 2012, 57, 3-8.
8.
Hook E.W. 3rd: Syphilis. Lancet 2017, 389, 1550-1557.
9.
Montano M.A., Dombrowski J.C., Dasgupta S., Golden M.R., Duerr A., Manhart L.E., et al.: Changes in sexual behavior and STI diagnoses among MSM initiating PrEP in a clinic setting. AIDS Behav 2019, 23, 548-555.
10.
Almeida V.C., Donalisio M.R., Cordeiro R.: Factors associated with reinfection of syphilis in reference centers for sexually transmitted infections. Rev Saude Publica 2017, 51, 64.
11.
Lynn W.A., Lightman S.: Syphilis and HIV: a dangerous combination. Lancet Infect Dis 2004, 4, 456-466.
12.
Chan P., Tang T.H.C., Kwong R.T.S., Chan L., Chan H.S.Y., Lam K.W., et al.: Effects of syphilis infection among HIV-1-positive individuals on suppressive antiretroviral therapy. AIDS Res Ther 2022, 19, 69.
13.
Papp J.R., Park I.U., Fakile Y., Pereira L., Pillay A., Bolan G.A.: CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep 2024, 73, 1-32.
14.
Wojas-Pelc A., Pastuszczak M., Serwin A., Rudnicka I., Majewski S., Czajkowski R., et al.: Syphilis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1: early and late syphilis. Dermatol Rev 2018, 105, 563-581.
15.
Society E.A.C. EACS Guidelines Version 12.0 October 2023 2023 [Available from: https://www.eacsociety.org/media/guidelines-12.0.pdf.
16.
Firlag-Burkacka E., Swiecki P., Cielniak I., Siwak E., Gizinska J., Bakowska E., et al.: High frequency of neurosyphilis in HIV-positive patients diagnosed with early syphilis. HIV Med 2016, 17, 323-326.
17.
Firlag-Burkacka E., Cielniak I., Swiecki P., Siwak E., Gizinska J., Bakowska E., et al.: The increasing prevalence of neurosyphilis and high serum VDRL titers in HIV positive patients – data from outpatient clinic in Warsaw, Poland (POLCA Cohort). HIV AIDS Rev 2013, 12, 34-36.
18.
Jinno S., Anker B., Kaur P., Bristow C.C., Klausner J.D.: Predictors of serological failure after treatment in HIV-infected patients with early syphilis in the emerging era of universal antiretroviral therapy use. BMC Infect Dis 2013, 13, 605.
19.
Spagnuolo V., Poli A., Galli L., Nozza S., Bossolasco S., Cernuschi M., et al.: Incidence and predictors of serological treatment response in early and late syphilis among people living with HIV. Open Forum Infect Dis 2019, 6, ofy324.
20.
Ghanem K.G., Moore R.D., Rompalo A.M., Erbelding E.J., Zenilman J.M., Gebo K.A.: Antiretroviral therapy is associated with reduced serologic failure rates for syphilis among HIV-infected patients. Clin Infect Dis 2008, 47, 258-265.
21.
Atsawawaranunt K., Kittiyaowamarn R., Phonrat B., Kamolratanakul S., Kangvalpornroj T., Dhitavat J.: Time to serological cure and associated factors among syphilis patients with and without HIV in a sexually transmitted infections center, Thailand. Sex Transm Dis 2020, 47, 283-289.
22.
Tong M.L., Lin L.R., Liu G.L., Zhang H.L., Zeng Y.L., Zheng W.H., et al.: Factors associated with serological cure and the serofast state of HIV-negative patients with primary, secondary, latent, and tertiary syphilis. PLoS One 2013, 8, e70102.
23.
Spagnuolo V., Poli A., Galli L., Cernuschi M., Nozza S., Maillard M., et al.: Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. J Int AIDS Soc 2014, 17, 19654.
24.
Sena A.C., Zhang X.H., Li T., Zheng H.P., Yang B., Yang L.G., et al.: A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy. BMC Infect Dis 2015, 15, 479.
25.
Knaute D.F., Graf N., Lautenschlager S., Weber R., Bosshard P.P.: Serological response to treatment of syphilis according to disease stage and HIV status. Clin Infect Dis 2012, 55, 1615-1622.
26.
Carlson J.A., Dabiri G., Cribier B., Sell S.: The immunopathobiology of syphilis: the manifestations and course of syphilis are determined by the level of delayed-type hypersensitivity. Am J Dermatopathol 2011, 33, 433-460.
27.
AIDS P.T.N. Zalecenia PTN AIDS 2024: Polskie Towarzystwo Naukowe AIDS; 2024 [Available from: https://www.ptnaids.pl/images/pliki/zalecenie_2024-caloscZAKLADKI.pdf.
28.
Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Muzny C.A., Park I., et al.: Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021, 70, 1-187.
